Vitiligo is a condition that causes loss of skin colour in patches due to the immune system attacking skin cells that produce melanin. It affects between 0.5% and 2% of the population and may be linked to other autoimmune diseases.
A new clinical trial is testing a monoclonal antibody – a targeted therapy designed to block the immune pathways that damage these cells.
SORRY, THIS STUDY WILL NO LONGER BE CONDUCTED IN NZ – updated 20 May 2026
For more information on current and future trials click here.
